References

Akhmedov, M., Zeynalova, P., & Fedenko, A. (2024). Multiple myeloma and infections in the era of novel treatment modalities. Leukemia Research, 143, 107544. https://doi.org/10.1016/j.leukres.2024.107544

Banerjee, R., Hosoya, H., Mikkilineni, L., Hansen, D. K., Wolf, J. L., & Lin, Y. (2025). Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma. Blood Cancer Journal, 15(1), 112. https://doi.org/10.1038/s41408-025-01320-x

Barroso, A., Estevinho, F., Hespanhol, V., Teixeira, E., Ramalho-Carvalho, J., & Araújo, A. (2024). Management of infusion-related reactions in cancer therapy: Strategies and challenges. ESMO Open, 9(3), 102922. https://doi.org/10.1016/j.esmoop.2024.102922

Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O’Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T.-M., Allred, A. J., Olyslager, Y., … Jagannath, S. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. The Lancet, 398(10297), 314–324. https://doi.org/10.1016/S0140-6736(21)00933-8

Bumma, N., Richter, J., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., Namburi, S., Pianko, M. J., Ye, J. C., Wu, K. L., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Dhodapkar, M. V. (2024). Linvoseltamab for treatment of relapsed/refractory multiple myeloma. Journal of Clinical Oncology, 42(22), 2702–2712. https://doi.org/10.1200/JCO.24.01008

Catamero, D., Ray, C., Purcell, K., Leahey, S., Esler, E., Rogers, S., Hefner, K., O’Rourke, L., Gray, K., Tolbert, J., Renaud, T., Patel, S., Hannemann, L., & Shenoy, S. (2024). Nursing considerations for the clinical management of adverse events associated with talquetamab in patients with relapsed or refractory multiple myeloma. Seminars in Oncology Nursing, 40(5), 151712. https://doi.org/10.1016/j.soncn.2024.151712

Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., Verona, R., Girgis, S., Yang, S., Goldsmith, R. B., Yao, X., Pillarisetti, K., Hilder, B. W., Russell, J., Goldberg, J. D., & Krishnan, A. (2022). Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. The New England Journal of Medicine, 387(24), 2232–2244. https://doi.org/10.1056/NEJMoa2204591

Chohan, K. L., Siegler, E. L., & Kenderian, S. S. (2023). CAR-T cell therapy: The efficacy and toxicity balance. Current Hematologic Malignancy Reports, 18(2), 9–18. https://doi.org/10.1007/s11899-023-00687-7

Czapka, M. T., Riedell, P. A., & Pisano, J. C. (2023). Infectious complications of CAR T-cell therapy: A longitudinal risk model. Transplant Infectious Disease, 25(Suppl. 1), e14148. https://doi.org/10.1111/tid.14148

Frey, N., & Porter, D. (2019). Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biology of Blood and Marrow Transplantation, 25(4), e123–e127. https://doi.org/10.1016/j.bbmt.2018.12.756

Galarza Fortuna, G. G., Banerjee, R., Savid-Frontera, C., Song, J., Morán-Segura, C. M., Nguyen, J. V., Lekakis, L., Fernandez-Pol, S., Samraj, A. N., Naresh, K. N., Vazquez-Martinez, M., Baz, R. C., Spiegel, J. Y., Mikkilineni, L., Gubatan, J. M., Sidana, S., de Menezes Silva Corraes, A., Kalariya, N. M., & Patel, K. K. (2024). Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer Journal, 14(1), 180. https://doi.org/10.1038/s41408-024-01167-8

Gonzalez Castro, L. N., & Dietrich, J. (2020). Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neuro-Oncology Practice, 8(3), 259–265. https://doi.org/10.1093/nop/npaa080

Hines, M. R., Knight, T. E., McNerney, K. O., Leick, M. B., Jain, T., Ahmed, S., Frigault, M. J., Hill, J. A., Jain, M. D., Johnson, W. T., Lin, Y., Mahadeo, K. M., Maron, G. M., Marsh, R. A., Neelapu, S. S., Nikiforow, S., Ombrello, A. K., Shah, N. N., Talleur, A. C., … Shah, N. N. (2023). Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplantation and Cellular Therapy, 29(7), 438.e1–438.e16. https://doi.org/10.1016/j.jtct.2023.03.006

Hong, J., Ahn, S.-Y., Lee, Y. J., Lee, J. H., Han, J. W., Kim, K. H., Yhim, H. Y., Nam, S. H., Kim, H. J., Song, J., Kim, S. H., Bang, S. M., Kim, J. S., Mun, Y. C., Bae, S. H., Kim, H. K., Jang, S., Park, R., Choi, H. S., … Korean Society of Hematology Thrombosis and Hemostasis Working Party. (2021). Updated recommendations for the treatment of venous thromboembolism. Blood Research, 56(1), 6–16. https://doi.org/10.5045/br.2021.2020083

Jain, M. D., Smith, M., & Shah, N. N. (2023). How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood, 141(20), 2430–2442. https://doi.org/10.1182/blood.2022017414

Korst, C. L. B. M., Groen, K., Bosman, P. W. C., van der Valk, F., Verkleij, C. P. M., Kruyswijk, S., de Ruijter, M. E. M., Heijink, D. M., Kuipers, M. T., Zweegman, S., & van de Donk, N. W. C. J. (2024). Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing. HemaSphere, 8(7), e132. https://doi.org/10.1002/hem3.132

Kowalski, A., Lykon, J., Diamond, B., Coffey, D., Kaddoura, M., Maura, F., Hoffman, J., Pandey, A., Kazandjian, D., & Landgren, O. (2025). Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. Blood Advances, 9(19), 4979–4986. https://doi.org/10.1182/bloodadvances.2025016911

Lakshman, A., & Kumar, S. K. (2022). Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. American Journal of Hematology, 97(1), 99–118. https://doi.org/10.1002/ajh.26379

LeBlanc, R., Bergstrom, D. J., Côté, J., Kotb, R., Louzada, M. L., & Sutherland, H. J. (2022). Management of myeloma manifestations and complications: The cornerstone of supportive care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) consensus guideline consortium. Clinical Lymphoma, Myeloma & Leukemia, 22(1), e41–e56. https://doi.org/10.1016/j.clml.2021.07.028

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs, K., Pasquini, M., DiPersio, J. F., van den Brink, M. R. M., … Neelapu, S. S. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625–638. https://doi.org/10.1016/j.bbmt.2018.12.758

Lee, J. C., Johnson, W. T., Hines, M., & Shah, N. N. (2025). Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Hematology/Oncology Clinics of North America, 39(3), 617–643. https://doi.org/10.1016/j.hoc.2025.02.005

Leinemann, V., & Krutter, S. (2024). ‘The last bridge’—How patients experience the CAR T-cell therapy. A qualitative study. European Journal of Oncology Nursing, 68, 102494. https://doi.org/10.1016/j.ejon.2023.102494

Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., Jethava, Y., Quach, H., Depaus, J., Yokoyama, H., Gabayan, A. E., Stevens, D. A., Nooka, A. K., Manier, S., Raje, N., Iida, S., … Mohty, M. (2023). Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nature Medicine, 29(9), 2259–2267. https://doi.org/10.1038/s41591-023-02528-9

Liang, E. C., & Sidana, S. (2023). Managing side effects: Guidance for use of immunotherapies in multiple myeloma. Hematology, American Society of Hematology Education Program, 2023(1), 348–356. https://doi.org/10.1182/hematology.2023000435

Lin, Y., Qiu, L., Usmani, S., Joo, C. W., Costa, L., Derman, B., Du, J., Einsele, H., Fernandez de Larrea, C., Hajek, R., Ho, P. J., Kastritis, E., Martinez-Lopez, J., Mateos, M.-V., Mikhael, J., Moreau, P., Nagarajan, C., Nooka, A., O’Dwyer, M., … Martin, T. (2024). Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: A report from the International Myeloma Working Group Immunotherapy Committee. The Lancet Oncology, 25(8), e374–e387. https://doi.org/10.1016/S1470-2045(24)00094-9

Little, J. S., Tandon, M., Hong, J. S., Nadeem, O., Sperling, A. S., Raje, N., Munshi, N., Frigault, M., Barmettler, S., & Hammond, S. P. (2023). Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Advances, 7(18), 5485–5495. https://doi.org/10.1182/bloodadvances.2023010524

Liu, A. J., Slavin, M. A., Harrison, S. J., & Teh, B. W. (2025). Infections during novel myeloma therapies. Leukemia & Lymphoma, 66(3), 420–432. https://doi.org/10.1080/10428194.2024.2428819

Ludwig, H., Terpos, E., van de Donk, N., Mateos, M.-V., Moreau, P., Dimopoulos, M.-A., Delforge, M., Rodriguez-Otero, P., San-Miguel, J., Yong, K., Gay, F., Einsele, H., Mina, R., Caers, J., Driessen, C., Musto, P., Zweegman, S., Engelhardt, M., Cook, G., … Sonneveld, P. (2023). Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network. The Lancet Oncology, 24(6), e255–e269. https://doi.org/10.1016/S1470-2045(23)00159-6

Markouli, M., Ullah, F., Unlu, S., Omar, N., Lopetegui-Lia, N., Duco, M., Anwer, F., Raza, S., & Dima, D. (2023). Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: Pathogenesis, prevention and management. Current Oncology, 30(7), 6330–6352. https://doi.org/10.3390/curroncol30070467

Mikkilineni, L., & Kochenderfer, J. N. (2021). CAR T cell therapies for patients with multiple myeloma. Nature Reviews Clinical Oncology, 18(2), 71–84. https://doi.org/10.1038/s41571-020-0427-6

Miller, K. C., Hamadeh, I., & Tan, C. R. (2025). Perspectives on talquetamab and its utility in the treatment of multiple myeloma: Safety, efficacy and place in therapy. Cancer Management and Research, 17, 743–756. https://doi.org/10.2147/CMAR.S441550

Mohan, M., Chakraborty, R., Bal, S., Nellore, A., Baljevic, M., D’Souza, A., Pappas, P. G., Berdeja, J. G., Callander, N., & Costa, L. J. (2023). Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. British Journal of Haematology, 203(5), 736–746. https://doi.org/10.1111/bjh.18909

Moreau, P., Girgis, S., & Goldberg, J. D. (2022). Teclistamab in relapsed or refractory multiple myeloma. Reply. The New England Journal of Medicine, 387(18), 1722–1723. https://doi.org/10.1056/NEJMc2211969

Munshi, N. C., Anderson, L. D., Jr., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., … San-Miguel, J. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. The New England Journal of Medicine, 384(8), 705–716. https://doi.org/10.1056/NEJMoa2024850

National Comprehensive Cancer Network. (2025b). NCCN Clinical Practice Guidelines in Oncology: Management of CAR T-cell and lymphocyte engager-related toxicities (Version 2.2026).

National Comprehensive Cancer Network. (2025a). NCCN Clinical Practice Guidelines in Oncology: Multiple myeloma (Version 2.2026).

Nooka, A. K., Rodriguez, C., Mateos, M. V., Manier, S., Chastain, K., Banerjee, A., Kobos, R., Qi, K., Verona, R., Doyle, M., Martin, T. G., & van de Donk, N. W. C. J. (2024). Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer, 130(6), 886–900. https://doi.org/10.1002/cncr.35107

Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., Thurston, C., Vedantham, S., Verhamme, P., Witt, D. M., Florez, I. D., Izcovich, A., Nieuwlaat, R., Ross, S., Schünemann, H. J., … Zhang, Y. (2020). American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Advances, 4(19), 4693–4738. https://doi.org/10.1182/bloodadvances.2020001830

Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S. P., Lesokhin, A. M., Lonial, S., Ludwig, H., Moreau, P., Patel, K., Ramasamy, K., & Mateos, M.-V. (2023). Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer Journal, 13(1), 116. https://doi.org/10.1038/s41408-023-00879-7

Ravi, G., & Costa, L. J. (2023). Bispecific T-cell engagers for treatment of multiple myeloma. American Journal of Hematology, 98(Suppl. 2), S13–S21. https://doi.org/10.1002/ajh.26628

Rees, J. H. (2022). Management of immune effector cell-associated neurotoxicity syndrome (ICANS). In N. Kröger, J. Gribben, C. Chabannon, I. Yakoub-Agha, & H. Einsele (Eds.), The EBMT/EHA CAR-T cell handbook (pp. 141–145). Springer. https://doi.org/10.1007/978-3-030-94353-0_27

Rejeski, K., Wang, Y., Albanyan, O., Muñoz, J., Sesques, P., Iacoboni, G., Lopez-Corral, L., Ries, I., Bücklein, V. L., Mohty, R., Dreyling, M., Baluch, A., Shah, B., Locke, F. L., Hess, G., Barba, P., Bachy, E., Lin, Y., Subklewe, M., & Jain, M. D. (2023). The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. American Journal of Hematology, 98(11), 1699–1710. https://doi.org/10.1002/ajh.27056

Richards, T., & Lee, H. (2018). Multiple myeloma: Risk stratification and toxicity management. Journal of the Advanced Practitioner in Oncology, 9(3), 329–335. https://doi.org/10.6004/jadpro.2018.9.3.10

Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S. R., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., … Giralt, S. (2023). Ide-cel or standard regimens in relapsed and refractory multiple myeloma. The New England Journal of Medicine, 388(11), 1002–1014. https://doi.org/10.1056/NEJMoa2213614

Rodriguez-Otero, P., Usmani, S., Cohen, A. D., van de Donk, N. W. C. J., Leleu, X., Gállego Pérez-Larraya, J., Manier, S., Nooka, A. K., Mateos, M. V., Einsele, H., Minnema, M., Cavo, M., Derman, B. A., Puig, N., Gay, F., Ho, P. J., Chng, W.-J., Kastritis, E., Gahrton, G., … International Myeloma Working Group. (2024). International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. The Lancet Oncology, 25(5), e205–e216. https://doi.org/10.1016/S1470-2045(24)00043-3

Romano, A., Storti, P., Marchica, V., Scandura, G., Notarfranchi, L., Craviotto, L., Di Raimondo, F., & Giuliani, N. (2021). Mechanisms of action of the new antibodies in use in multiple myeloma. Frontiers in Oncology, 11, 684561. https://doi.org/10.3389/fonc.2021.684561

San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N. W. C. J., Dytfeld, D., Sidana, S., … Einsele, H. (2023). Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. The New England Journal of Medicine, 389(4), 335–347. https://doi.org/10.1056/NEJMoa2303379

Schuster, S. J., Maziarz, R. T., Rusch, E. S., Li, J., Signorovitch, J. E., Romanov, V. V., Locke, F. L., & Maloney, D. G. (2020). Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Advances, 4(7), 1432–1439. https://doi.org/10.1182/bloodadvances.2019001304

Shimabukuro-Vornhagen, A., Böll, B., Schellongowski, P., Valade, S., Metaxa, V., Azoulay, E., & von Bergwelt-Baildon, M. (2022). Critical care management of chimeric antigen receptor T-cell therapy recipients. CA: A Cancer Journal for Clinicians, 72(1), 78–93. https://doi.org/10.3322/caac.21702

Somay, K., Azakli, H., Chahine, J. J., Loughney, T. M., & Ozdemirli, M. (2025). Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder? Blood Cancer Journal, 15(1), 117. https://doi.org/10.1038/s41408-025-01319-4

Sperling, A. S., & Anderson, K. C. (2021). Facts and hopes in multiple myeloma immunotherapy. Clinical Cancer Research, 27(16), 4468–4477. https://doi.org/10.1158/1078-0432.CCR-20-3600

U.S. Food and Drug Administration. (2025). FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma [Press release]. FDA approval notice.

van de Donk, N. W. C. J., & Zweegman, S. (2024). Monoclonal antibodies in the treatment of multiple myeloma. Hematology/Oncology Clinics of North America, 38(2), 337–360. https://doi.org/10.1016/j.hoc.2023.12.002

Wang, X., Zhao, A., Zhu, J., & Niu, T. (2024). Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: A systematic review and meta-analysis of prospective clinical trials. Frontiers in Immunology, 15, 1348955. https://doi.org/10.3389/fimmu.2024.1348955

Zuo, X., & Liu, D. (2022). Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma. Hematology, 27(1), 1110–1121. https://doi.org/10.1080/16078454.2022.2124694